FLT3 and cerebral cavernous malformation: Five compounds showed some degree of rescue in all three CCM models (Dataset EV2): the FLT3 angiogenesis inhibitor ENMD‐2076, the PKC/phospholipase A2/D inhibitor DL‐erythro‐dihydrosphingosine, the PI3K/Akt/mTor pathway inhibitor ridaforolimus, the muscarinic acetylcholine receptor antagonist DL‐homatropine hydrobromide, and 13‐cis‐retinoic acid, which has anti‐inflammatory and anti‐tumorigenic effects.